Vegfrs in Neoplastic Angiogenesis and Prospects for Therapy Оf Brain Tumors

Abstract

Vegfrs in Neoplastic Angiogenesis and Prospects for Therapy оf Brain Tumors

Uterine leiomyoma in women of reproductive age after previously performed uterine artery embolization, focused ultrasound ablation controlled by MRI and myomectomy: molecular, morphological and clinical features

“…HIF-lα является ведущим транскрипционным регулятором генов, таких как VEGF, рецептора урокиназы, тиро-зингидролазы, эндотелина, синтазы оксида азота, эритропоэтина и ряда гликолитических ферментов, ответственных за реакцию на кислородную недоста-точность [13][14][15]. Следует отметить, что HIF-1α по-стоянно присутствует в клетке, но в условиях нор-моксии характеризуется быстрым полураспадом.…”

Trends in Malignant Glioma Monoclonal Antibody Therapy

“…Ramucirumab, a monoclonal antibody to VEGFR-2, has successfully undergone phase III clinical trial as a therapeutic agent for gastric cancer and gastro-esophageal junction carcinoma [ 58 ]. Korchagina et al consider selective VEGFR-2 inhibition, supported by hypoxia-inducible factor 1 and placental growth factor suppression, as a perspective means of glioma targeted therapy [ 59 ]. According to Ikeda et al , VEGFR-1 has a much weaker tyrosine kinase activity [ 60 ] and can abrogate VEGF angiogenetic effect exerted via VEGFR-2, acting as a natural angiogenesis inhibitor [ 43 ].…”